Read More

Sarepta Therapeutics Reports Clinical Results From Phase 2 MOMENTUM Study Of SRP-5051 In Patients With Duchenne Muscular Dystrophy Amenable To Skipping Exon 51; Delivered Mean Exon Skipping Of 10.79% And Mean Dystrophin Expression Of 6.55%

Results suggest a highly potent next-generation treatment that could offer greater efficacy with less frequent dosing SRP-5051 dosed monthly at 30 mg/kg delivered mean exon skipping of 10.79% and mean

SRPT

Read More

Scully Royalty Provides Update On Scully Mine

Scully Royalty Ltd. (the "Company") (NYSE:SRL) is pleased to announce that it has filed its annual report on form 20-F with the Securities and Exchange Commission, and also provides the following corporate

SRL